Tao Tao1, Shuqiu Chen1, Bin Xu1, Chunhui Liu1, Yiduo Wang1, Yeqing Huang1, Ming Chen1. 1. 1 Department of Urology, Affiliated Zhongda Hospital, Medical School, 2 Surgical Research Center, Medical School, 3 Institute of Urology, Southeast University, Nanjing 210009, China.
Abstract
OBJECTIVE: Emerging evidence shows that microRNAs (miRNAs) function as tumor suppressors or oncogenes in human carcinogenesis. A single nucleotide polymorphism (SNP) located in the pri-miRNA promoter may affect the processing and expression of mature miRNA. However, previous studies showed conflicting results regarding the association of hsa-miR-34b/c rs4938723 T > C promoter polymorphism with cancer. Therefore, we conducted a meta-analysis to determine the association of polymorphism with cancer risk. METHODS: A computerized search of PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI) for publications on hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk was performed and the genotype data were analyzed in a meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association. Test of heterogeneity, cumulative meta-analysis, sensitivity analysis and assessment of bias were performed in our meta-analysis by STATA software 12.0. RESULTS: There was no significant association between hsa-miR-34b/c rs4938723 polymorphism and overall cancer risk in the comparison models. Moreover, subgroup analysis revealed that the variant CT (OR =1.19, 95% CI: 1.03-1.37) and CC/CT (OR =1.18, 95% CI: 1.03-2.35) genotypes were associated with an increased risk of hepatocellular carcinoma (HCC) compared with wild-type TT genotype. However, a decreased risk of colorectal cancer (CRC) was found in the genetic model of CC/TT (OR =0.66, 95% CI: 0.47-0.92) and CC/CTTT (OR =0.67, 95% CI: 0.49-0.93). CONCLUSIONS: The results suggest that hsa-miR-34b/c rs4938723 polymorphism may play an opposite role in different types of cancer based on current studies, which is the main origin of heterogeneity in this meta-analysis. Further large-scale studies and functional studies between this polymorphism and cancer risk are warranted.
OBJECTIVE: Emerging evidence shows that microRNAs (miRNAs) function as tumor suppressors or oncogenes in humancarcinogenesis. A single nucleotide polymorphism (SNP) located in the pri-miRNA promoter may affect the processing and expression of mature miRNA. However, previous studies showed conflicting results regarding the association of hsa-miR-34b/c rs4938723 T > C promoter polymorphism with cancer. Therefore, we conducted a meta-analysis to determine the association of polymorphism with cancer risk. METHODS: A computerized search of PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI) for publications on hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk was performed and the genotype data were analyzed in a meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association. Test of heterogeneity, cumulative meta-analysis, sensitivity analysis and assessment of bias were performed in our meta-analysis by STATA software 12.0. RESULTS: There was no significant association between hsa-miR-34b/c rs4938723 polymorphism and overall cancer risk in the comparison models. Moreover, subgroup analysis revealed that the variant CT (OR =1.19, 95% CI: 1.03-1.37) and CC/CT (OR =1.18, 95% CI: 1.03-2.35) genotypes were associated with an increased risk of hepatocellular carcinoma (HCC) compared with wild-type TT genotype. However, a decreased risk of colorectal cancer (CRC) was found in the genetic model of CC/TT (OR =0.66, 95% CI: 0.47-0.92) and CC/CTTT (OR =0.67, 95% CI: 0.49-0.93). CONCLUSIONS: The results suggest that hsa-miR-34b/c rs4938723 polymorphism may play an opposite role in different types of cancer based on current studies, which is the main origin of heterogeneity in this meta-analysis. Further large-scale studies and functional studies between this polymorphism and cancer risk are warranted.
Authors: John F Carlquist; Benjamin D Horne; Chrissa Mower; James Park; John Huntinghouse; Jason T McKinney; Joseph B Muhlestein; Jeffrey L Anderson Journal: J Thromb Thrombolysis Date: 2010-10 Impact factor: 2.300
Authors: Guido T Bommer; Isabelle Gerin; Ying Feng; Andrew J Kaczorowski; Rork Kuick; Robert E Love; Yali Zhai; Thomas J Giordano; Zhaohui S Qin; Bethany B Moore; Ormond A MacDougald; Kathleen R Cho; Eric R Fearon Journal: Curr Biol Date: 2007-07-26 Impact factor: 10.834
Authors: Tao Tao; Yingyi Wang; Hui Luo; Lei Yao; Lin Wang; Jiajia Wang; Wei Yan; Junxia Zhang; Huibo Wang; Yan Shi; Yu Yin; Tao Jiang; Chunsheng Kang; Ning Liu; Yongping You Journal: Eur J Cancer Date: 2013-06-26 Impact factor: 9.162
Authors: Eman A Toraih; Manal S Fawzy; Eman A Mohammed; Mohammad H Hussein; Mohamad M El-Labban Journal: Mol Diagn Ther Date: 2016-12 Impact factor: 4.074